

# News Release

## CONTACTS:

J.C. Weigelt  
Investor Relations  
Tel 651 756 4347  
jweigelt@sjm.com

Amy Jo Meyer  
Media Relations  
Tel 651 756 3029  
ameyer@sjm.com

## **St. Jude Medical Seeks Retraction of *Heart Rhythm Journal* Manuscript by Dr. Robert Hauser**

Research undercounted and excluded MAUDE data reports for Medtronic product resulting in substantial factual errors

ST. PAUL, Minn. – April 6, 2012 – St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced it is seeking a retraction of the manuscript accepted for publication in the *Heart Rhythm Journal* by Dr. Robert Hauser, et al., titled, “Deaths Caused by the Failure of Riata and Riata ST Implantable Cardioverter-Defibrillator Leads.”

The manuscript presented results from an analysis that assessed the number of death reports associated with St. Jude Medical Riata® and Riata ST defibrillation leads compared with Medtronic Quattro Secure leads. This assessment was based on a search of the U.S. Food and Drug Administration (FDA) Manufacturers and User Facility Device Experience (MAUDE) database. In the analysis, the authors classified the deaths in one of three categories (lead related, indeterminate or not lead related) and drew conclusions about how Riata and Riata ST leads compare with Medtronic's Quattro Secure leads. Using the same search criteria outlined in the manuscript, the company has identified that Dr. Hauser's research substantially undercounted total deaths in the MAUDE database for Quattro Secure, which therefore resulted in substantial errors related to how Riata and Riata ST leads compared to the Quattro Secure lead.

### **Inaccurate Facts and Bias Analysis**

St. Jude Medical's independent search of the MAUDE database found 377 reports of deaths involving Quattro Secure leads, not 62 as stated by Dr. Hauser in a manuscript posted online and accepted for publication in the *Heart Rhythm Journal*. St. Jude Medical's analysis of Riata and Riata ST lead events found in the MAUDE database also indicate that Dr. Hauser did not report an additional three deaths, which would change the number from 71 in Dr. Hauser's manuscript to 74.

Dr. Hauser's manuscript is mistaken or misleading in a number of other respects as well. It is important to note that Dr. Hauser has selectively chosen to include only one Quattro Secure lead model in his analysis versus all of the Riata and Riata ST models for St. Jude Medical. Although we did not include those lead models in our analysis, there are also deaths associated with those additional model numbers.

There is a range of detail available in MAUDE reports, with Medtronic generally reporting the least amount of detail compared with other companies in the industry. In addition, the detail and rate of reporting has increased since Medtronic's Cardiac Rhythm Management business received a warning letter from the Food and Drug Administration in 2009, meaning events prior to this date in the analysis

may have been under-detected. An analysis of “lead-related” deaths is biased against manufacturers that more transparently report on device malfunctions. A less biased manner of comparison would combine “lead-related” and “indeterminate” deaths, because the resulting number only excludes the reports that are clearly not lead-related.

Finally, the entire premise of the comparison of a recalled silicone-only insulated lead versus Quattro Secure, which is a product insulated with a polyurethane outer insulation, is flawed. It is acknowledged in the industry that silicone-insulated leads are more susceptible to abrasion than leads with newer insulation materials. A more appropriate comparison would have been to compare the Riata and Riata ST leads to other recalled leads. For example, there are approximately 1,200 MAUDE death reports associated with the recalled Medtronic Sprint Fidelis lead, out of approximately 268,000 leads sold worldwide, or a rate of 447.8 per 100,000. For Sprint Fidelis leads, note that many cases indicate “under litigation” in the MAUDE report and no detail on the cause of failure is provided. Alternatively, Dr. Hauser could have compared Quattro Secure to St. Jude Medical’s currently available Durata® lead, which the company is confident would have resulted in a favorable comparison as well.

St. Jude Medical was not consulted prior to the publication, nor asked to validate any of the data against its returns analyses. Since the manuscript was published, the company has spent more than 300 hours attempting to reach the same conclusions as Dr. Hauser, but can find no way of analyzing the MAUDE database that reproduces the same numbers reported in the manuscript. The company has identified duplicate reports, inconsistent categorizations and failures to include all available reports.

The method of the study itself, using MAUDE reports to compare devices, is not appropriate. The home page of the Food and Drug Administration’s MAUDE database even states, “MAUDE data is not intended to be used either to evaluate rates of adverse events or to compare adverse event occurrence rates across devices.”

### **Conclusion**

Given these factual errors and biased analysis, we are requesting that the manuscript immediately be retracted by the authors and removed from online publication by the official journal of the Heart Rhythm Society.

### **About St. Jude Medical**

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit [sjm.com](http://sjm.com).

### **Forward-Looking Statements**

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ



St. Jude Medical, Inc.  
Global Headquarters  
One St. Jude Medical Drive  
St. Paul, MN 55117-9913 USA  
Tel 651 756 2000  
sjm.com

materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.